Related Experiment Video
Updated: Aug 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
Herng-Der Chern1, Tzuu-Huei Ueng, Yi-Ping Fu
1Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|January 18, 2006
Summary
A novel gene mutation, G-65/C, impacts warfarin sensitivity in Chinese-Taiwanese patients with prosthetic heart valves. This finding helps explain variations in warfarin dosing and improves patient care.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Warfarin is crucial for preventing thromboembolism in patients with prosthetic heart valves.
- Cytochrome P450 2C9 (CYP2C9) is the primary enzyme metabolizing warfarin, but known genetic variations don't fully explain dose discrepancies in Chinese-Taiwanese populations.
- This study investigated a newly identified CYP2C9 polymorphism's role in warfarin sensitivity.
Purpose of the Study:
- To identify and characterize novel CYP2C9 polymorphisms.
- To investigate the association between these polymorphisms and warfarin dose requirements.
- To understand inter-ethnic variations in warfarin metabolism.
Main Methods:
- Examined warfarin dose requirements in 239 Chinese-Taiwanese patients.
- Conducted DNA sequencing and CYP2C9 genotyping (PCR-RFLP) on patients and healthy controls (Chinese-Taiwanese, Caucasian, African-American).
- Analyzed allelic frequencies and genotypes using chi-squared and Fisher's exact tests.
Main Results:
- A novel single nucleotide polymorphism, G-65/C, was identified in intron 3 of CYP2C9.
- The C-65 allele frequency varied significantly across ethnic groups (0.125 African-American, 0.058 Chinese-Taiwanese, ~0 Caucasian).
- Patients carrying the C-65 variant (heterozygous or homozygous) required approximately half the standard warfarin dose.
Conclusions:
- The novel intronic G-65/C mutation exhibits inter-racial differences in allelic frequency.
- This mutation significantly affects warfarin sensitivity in Chinese-Taiwanese patients undergoing mitral valve replacement.
- The findings contribute to personalized warfarin therapy by identifying a key genetic determinant of drug response.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...